Hadassah

Hadassah and Yale Researchers Find Peptide Prevents Disease in Mice

Thursday, Jun 13 2013

Researchers from the Hadassah University Medical Center's Department of Bone Marrow Transplantation, jointly with Yale University and BioIncept, an American-based biotechnology company, have discovered that a certain peptide released by a fetus during pregnancy, called a "pre-implantation factor" (PIF) is effective in preventing graft-versus-host disease (GVHD) in mice, following a bone marrow transplant.

Bone marrow transplants, performed to treat severe hematologic malignancies, the researchers explain, "often lead to potentially fatal, acute GVHD, despite attempts at better donor–recipient matching and/or use of immunosuppressive agents."

When a fetus releases PIF during its early stages of development (mainly during the first two trimesters), it enables the rooting of the fetus in its mother's uterus, regulating immune activity and preventing the mother's rejection of the fetus, without harming the mother's immune system. Given PIF's immune regulating properties and its effectiveness in developing maternal tolerance, it could logically have the potential to regulate the immune response in GVHD. In addition, the authors note that synthetic PIF treatment has proven effective in preventing immune attacks in nonpregnant models of autoimmunity.

In this study, the researchers transplanted bone marrow and spleen cells from donors into mice and then treated them with PIF for two weeks. Short-term PIF administration reduced acute GVHD and increased survival for up to four months following a transplant. This effect was coupled with decreased skin inflammation and decreased liver inflammation, as well as reduced colon ulceration--all without interfering with the positive effects of the transplant.

"Overall," the researchers concluded, "our data demonstrate that PIF protects against GVHD long term by reducing both target organ and systemic inflammation and by decreasing oxidative stress." This research joins other studies conducted by the Department of Bone Marrow Transplantation, which demonstrated the effectiveness of the peptide in preventing diabetes and central nervous system inflammation.

Since recent tests in the United States have successfully ruled out any toxic or negative side effects in healthy animals as a result of this peptide treatment, researchers can now take the next step and begin clinical trials in humans. According to Prof. Reuven Or, head of Hadassah's Department of Bone Marrow Transplantation, "In the next few months, Hadassah researchers will focus on preparing for the upcoming clinical trial and making sure we have all necessary documents and approvals in order to begin."

Read the abstract in the Biology of Blood and Marrow Transplantation Journal>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Mar 8 2019

Quick Action at Hadassah’s Milstein Heart Center Saves Exuberant Hasidic Dancer

“You can’t dance at all the weddings” is a common Hebrew and Yiddish expression. For Mr. Cohen (not his real name), a 49-year-old teacher, the wedding of a friend’s son was an occasion to get together with classmates from his post-high school yeshiva days when he was 19. Inclined to dance with joy at weddings, this twinkle-eyed, bearded Hassid increased the tempo in the presence of his long-ago pals.

READ MORE ›
alt_text

Friday, Mar 8 2019

Hadassah Surgeon Uses Revolutionary Surgery and Stem Cells to Restore Mobility

He grew up on the Mediterranean coast in Ashkelon, but Eyal Turgeman dreamed of becoming an African wilderness tour guide.

READ MORE ›
alt_text

Wednesday, Feb 27 2019

A Double Stroke at the Dead Sea

Imagine having a double stroke in two different arteries while on a day trip at the Dead Sea! What could be the chances of survival?

READ MORE ›
alt_text

Wednesday, Feb 27 2019

A Miracle in the Medical Intensive Care Unit at Hadassah —as recalled by Dr. Sigal Sviri, Director

On a cold December morning, a 26-year-old mother of two started developing flu symptoms, with fever, headache, and shortness of breath.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More